The Economic Burden of Patients with Diabetic Peripheral Neuropathic Pain Based on a Real-World Study in China.

IF 2.1 Q3 HEALTH CARE SCIENCES & SERVICES
ClinicoEconomics and Outcomes Research Pub Date : 2025-06-13 eCollection Date: 2025-01-01 DOI:10.2147/CEOR.S501243
Rosa Wang, Dennis D Xuan, Jianwei Xuan, Dong Dai, Xin Ye, Xiaohan Hu
{"title":"The Economic Burden of Patients with Diabetic Peripheral Neuropathic Pain Based on a Real-World Study in China.","authors":"Rosa Wang, Dennis D Xuan, Jianwei Xuan, Dong Dai, Xin Ye, Xiaohan Hu","doi":"10.2147/CEOR.S501243","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Currently, there is no specific characterization of the economic burden of Diabetic Peripheral Neuropathic Pain (DPNP) in most Asian countries. The purpose of this study was to understand the economic burden of DPNP in China from a healthcare system perspective.</p><p><strong>Methods: </strong>The analysis was conducted using the SuValue<sup>®</sup> database, a large electronic medical record (EMR) database which covers 182 hospitals across 22 provinces in China. A 12-month baseline and 12-month follow-up period were used to compare healthcare resource utilization and costs before and after the initial diagnosis of DPNP.</p><p><strong>Results: </strong>A total of 7373 adult patients with DPNP were identified and 4220 (57.24%) patients were treated. Analgesics (n=2044, 48.44%) and anti-inflammatory drugs (n=1990, 47.16%) were the most used treatments. Among DPNP treated patients, the mean (SD) total all-cause healthcare costs during follow-up period were 8980.83 (17,721.48) CNY, with a 4446.48 CNY increase (p-value < 0.001) from 4534.35 (9791.93) CNY at baseline. The cost increase was primarily driven by an increase in hospitalization and medication costs after the DPNP diagnosis. A similar trend in the treatment pattern and total cost increase after DPNP diagnosis was also found in a sensitivity analysis when excluding over-the-counter (OTC) products from the analysis.</p><p><strong>Conclusion: </strong>DPNP is associated with significantly increased utilization of healthcare services and costs for patients in China.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"437-446"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174928/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ClinicoEconomics and Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CEOR.S501243","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Currently, there is no specific characterization of the economic burden of Diabetic Peripheral Neuropathic Pain (DPNP) in most Asian countries. The purpose of this study was to understand the economic burden of DPNP in China from a healthcare system perspective.

Methods: The analysis was conducted using the SuValue® database, a large electronic medical record (EMR) database which covers 182 hospitals across 22 provinces in China. A 12-month baseline and 12-month follow-up period were used to compare healthcare resource utilization and costs before and after the initial diagnosis of DPNP.

Results: A total of 7373 adult patients with DPNP were identified and 4220 (57.24%) patients were treated. Analgesics (n=2044, 48.44%) and anti-inflammatory drugs (n=1990, 47.16%) were the most used treatments. Among DPNP treated patients, the mean (SD) total all-cause healthcare costs during follow-up period were 8980.83 (17,721.48) CNY, with a 4446.48 CNY increase (p-value < 0.001) from 4534.35 (9791.93) CNY at baseline. The cost increase was primarily driven by an increase in hospitalization and medication costs after the DPNP diagnosis. A similar trend in the treatment pattern and total cost increase after DPNP diagnosis was also found in a sensitivity analysis when excluding over-the-counter (OTC) products from the analysis.

Conclusion: DPNP is associated with significantly increased utilization of healthcare services and costs for patients in China.

基于中国真实世界研究的糖尿病周围神经性疼痛患者的经济负担
目的:目前,大多数亚洲国家对糖尿病周围神经性疼痛(DPNP)的经济负担没有具体的描述。本研究的目的是从医疗系统的角度来了解中国DPNP的经济负担。方法:使用SuValue®数据库进行分析,该数据库是一个大型电子病历数据库,涵盖了中国22个省份的182家医院。12个月的基线期和12个月的随访期用于比较DPNP初始诊断前后的医疗资源利用和成本。结果:共发现成年DPNP患者7373例,治疗4220例(占57.24%)。镇痛药(n=2044,占48.44%)和抗炎药(n=1990,占47.16%)是使用最多的药物。DPNP治疗患者随访期间的全因医疗费用平均(SD)为8980.83 (17721.48)CNY,较基线时的4534.35 (9791.93)CNY增加4446.48 CNY (p值< 0.001)。费用增加的主要原因是DPNP诊断后住院和药物费用的增加。在排除非处方(OTC)产品的敏感性分析中,也发现了DPNP诊断后治疗模式和总费用增加的类似趋势。结论:DPNP与中国患者医疗服务利用率和医疗费用的显著增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ClinicoEconomics and Outcomes Research
ClinicoEconomics and Outcomes Research HEALTH CARE SCIENCES & SERVICES-
CiteScore
3.70
自引率
0.00%
发文量
83
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信